This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval
by Zacks Equity Research
Puma Biotechnology, Inc's (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx.
Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.
Are Options Traders Betting on a Big Move in Puma Biotechnology (PBYI) Stock?
by Zacks Equity Research
Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately.
Key FDA Events to Watch Out for in Jul 2017
by Arpita Dutt
Will the FDA follow the advice of its advisory panel and give its nod to Puma's (PBYI) neratinib?
AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use
by Zacks Equity Research
AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.
Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval
by Zacks Equity Research
Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.
Pfizer Provides Final Update on Phase II Talazoparib Study
by Zacks Equity Research
Pfizer Inc. (PFE) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1/2 positive (gBRCA+) mutations, showing anti-tumor activity
3 Hot Biotech Stocks to Buy in June
by Arpita Dutt
While drug pricing will remain a headline risk, here are a few biotech stocks that have performed well YTD and look well-positioned.
Puma Soaring After Neratinib FDA Panel Win, Time to Buy?
by Zacks Equity Research
Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast cancers.
Will Puma Biotechnology (PBYI) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Puma Biotechnology Inc (PBYI).
Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) moved big last session, as its shares rose over 30% on the day.
Are Options Traders Betting on a Big Move in Puma (PBYI) Stock?
by Zacks Equity Research
Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately.
Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now
by Zacks Equity Research
On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI).
Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) reported a first-quarter 2017 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.
Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) is expected to report first-quarter 2017 results later this month.
Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) reported a fourth-quarter 2016 loss of $2.04 per share (including the impact of stock-based compensation expenses), wider than both the Zacks Consensus Estimate of a loss of $2.02.
Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.
Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).